CNS Pharmaceuticals, Inc. (CNSP) stock
CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.15+0.67 (+19.25%)
Close on Nov 17, 2026Market cap $6.07MP/E –Yield –
Earnings
CNS Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of CNS Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2024ended Mar 31, 2024 | May 16, 2024during market hours | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 15, 2023before the open | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023before the open | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023before the open | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022before the open | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022after the close | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 3, 2022before the open | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 13, 2021before the open | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 12, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
CNS Pharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When CNS Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases CNS Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Update
- Update
- News
- Update
- Update
- News
- Update
- News
- News
- News
- News
- Results
See a number that looks wrong?